CN101668768B - 制备a2a-腺苷受体激动剂及其多晶型物的方法 - Google Patents
制备a2a-腺苷受体激动剂及其多晶型物的方法 Download PDFInfo
- Publication number
- CN101668768B CN101668768B CN2007800529263A CN200780052926A CN101668768B CN 101668768 B CN101668768 B CN 101668768B CN 2007800529263 A CN2007800529263 A CN 2007800529263A CN 200780052926 A CN200780052926 A CN 200780052926A CN 101668768 B CN101668768 B CN 101668768B
- Authority
- CN
- China
- Prior art keywords
- temperature
- compound
- under
- structural formula
- vacuum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N CNC(c1c[n](-c2nc(N)c3nc[n]([C@@H]([C@@H]4O)O[C@H](CO)[C@H]4O)c3n2)nc1)=O Chemical compound CNC(c1c[n](-c2nc(N)c3nc[n]([C@@H]([C@@H]4O)O[C@H](CO)[C@H]4O)c3n2)nc1)=O LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 description 2
- 0 *c1nc(N)c2nc[n]([C@@]([C@@]3O)O[C@@](CO)[C@@]3O)c2n1 Chemical compound *c1nc(N)c2nc[n]([C@@]([C@@]3O)O[C@@](CO)[C@@]3O)c2n1 0.000 description 1
- FZDLWIVJDVIJGW-CLDRPODSSA-N CCOC(/C(/C=O)=C/Nc1c2nc[n]([C@@H]([C@@H]3O)O[C@H](CO)[C@H]3O)c2nc(-[n]2ncc(C(OCC)=O)c2)n1)=O Chemical compound CCOC(/C(/C=O)=C/Nc1c2nc[n]([C@@H]([C@@H]3O)O[C@H](CO)[C@H]3O)c2nc(-[n]2ncc(C(OCC)=O)c2)n1)=O FZDLWIVJDVIJGW-CLDRPODSSA-N 0.000 description 1
- MHWIWFJVWMUGFZ-RVXWVPLUSA-N CCOC(c1c[n](Cc2nc(N)c3nc[n]([C@@H]([C@@H]4O)O[C@H](CO)[C@H]4O)c3n2)nc1)=O Chemical compound CCOC(c1c[n](Cc2nc(N)c3nc[n]([C@@H]([C@@H]4O)O[C@H](CO)[C@H]4O)c3n2)nc1)=O MHWIWFJVWMUGFZ-RVXWVPLUSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Description
标记 | 13C化学位移(ppm) | 1H化学位移(ppm) | 多重度,裂分(Hz) |
2 | 150.5或150.3 | - | |
4 | 156.4 | - | |
4a | 117.9 | - | |
6 | 140.0 | 8.41 | s |
7a | 150.5或150.3 | - | |
1′ | 86.9 | 5.94 | D,6.2 |
2′ | 73.7 | 4.62 | m |
2′-OH | - | 5.50 | D,6.2 |
3′ | 70.5 | 4.17 | m |
3′-OH | - | 5.23 | D,4.7 |
4′ | 85.7 | 3.96 | m |
5′ | 61.5 | 3.67,3.57 | m |
5′-OH | - | 5.02 | D,5.7 |
A | 140.9 | 8.07 | D,0.8 |
B | 120.2 | - | |
C | 129.6 | 8.95 | D,0.8 |
D | 161.7 | - | |
E | 25.6 | 2.76 | D,4.6 |
NH2 | - | 7.77 | br |
NH | - | 8.35 | Q,4.6 |
原子a | 13C化学位移(ppm) | 1H化学位移(ppm) | 多重度,裂分(Hz) |
21(主) | 192.4 | 9.96 | d,3.6 |
21(次) | 187.6 | 9.83 | s |
22(次) | 167.1 | - | - |
22(主) | 165.2 | - | - |
15(次) | 161.8 | - | - |
15(主) | 161.7 | - | - |
6(主) | 153.1 | - | - |
6(次) | 152.9 | - | - |
2(次) | 149.4 | - | - |
2(主) | 149.3 | - | - |
19(次) | 148.0 | 9.22 | d,13.0 |
4(次) | 147.9 | - | - |
4(主) | 147.8 | - | - |
19(主) | 147.5 | 9.26 | d,12.4,d,3.6 |
8(主) | 144.9 | 8.87 | s |
8(次) | 144.7 | 8.85 | s |
12 | 143.1 | 8.20-8.23 | m |
14(次) | 132.8 | 9.20 | d,~0.7 |
14(主) | 132.6 | 9.12 | d,~0.7 |
5(主) | 120.7 | - | - |
5(次) | 120.6 | - | - |
13 | 116.7 | - | - |
20(次) | 107.2 | - | - |
20(主) | 106.1 | - | - |
1′(主) | 87.9 | 6.07 | d,5.3 |
1′(次) | 87.9 | 6.06 | d,5.3 |
4′ | 85.8 | 4.02 | q,3.9 |
2′(次) | 74.1 | 4.62 | q,~5.4 |
2′(主) | 74.1 | 4.61 | q,~5.4 |
3′ | 70.1 | 4.22 | q,4~ |
5′ | 61.0 | 3.62,3.73 | m |
23,16 | 60.3-60.8 | 4.25~4.39 | m |
17,24 | 14.1-14.2 | 1.28~1.38 | m |
18(主) | - | 12.51 | d,12.4 |
18(次) | - | 11.47 | d,13.0 |
2′-OH(主) | - | 5.63 | d,6.1 |
2′-OH(次) | - | 5.62 | d,6.1 |
3′-OH | - | 5.30 | d,5.1 |
5′-OH | - | 5.08 | t,5.5 |
标记 | 13C化学位移(ppm) | 1H化学位移(ppm) | 多重度,裂分(Hz) |
2 | 150.5或150.3 | - | |
4 | 156.4 | - | |
4a | 117.9 | - | |
6 | 140.0 | 8.41 | s |
7a | 150.5或150.3 | - | |
1′ | 86.9 | 5.94 | D,6.2 |
2′ | 73.7 | 4.62 | m |
2′-OH | - | 5.50 | D,6.2 |
3′ | 70.5 | 4.17 | m |
3′-OH | - | 5.23 | D,4.7 |
4′ | 85.7 | 3.96 | m |
5′ | 61.5 | 3.67,3.57 | m |
5′-OH | - | 5.02 | D,5.7 |
A | 140.9 | 8.07 | D,0.8 |
B | 120.2 | - | |
C | 129.6 | 8.95 | D,0.8 |
D | 161.7 | - | |
E | 25.6 | 2.76 | D,4.6 |
NH2 | - | 7.77 | br s |
NH | - | 8.35 | Q,4.6 |
Claims (13)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2007/069190 WO2008143667A1 (en) | 2007-05-17 | 2007-05-17 | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210240476 Division CN102863494A (zh) | 2007-05-17 | 2007-05-17 | 制备a2a-腺苷受体激动剂及其多晶型物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101668768A CN101668768A (zh) | 2010-03-10 |
CN101668768B true CN101668768B (zh) | 2012-08-29 |
Family
ID=38543556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800529263A Active CN101668768B (zh) | 2007-05-17 | 2007-05-17 | 制备a2a-腺苷受体激动剂及其多晶型物的方法 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2158208B1 (zh) |
JP (1) | JP5349461B2 (zh) |
KR (2) | KR20140041965A (zh) |
CN (1) | CN101668768B (zh) |
AU (1) | AU2007353780B2 (zh) |
CA (1) | CA2685589C (zh) |
ES (1) | ES2537959T3 (zh) |
HK (1) | HK1140771A1 (zh) |
IL (1) | IL201856A (zh) |
MX (1) | MX2009012369A (zh) |
NO (1) | NO341758B1 (zh) |
NZ (1) | NZ580940A (zh) |
PT (1) | PT2158208E (zh) |
WO (1) | WO2008143667A1 (zh) |
ZA (1) | ZA200907565B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397442A (zh) * | 2015-07-28 | 2017-02-15 | 国药集团国瑞药业有限公司 | 一种瑞加德松的纯化方法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
PL1989214T3 (pl) | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
CZ308577B6 (cs) | 2011-08-18 | 2020-12-16 | Farmak, A. S. | Způsob přípravy 2-(4-methoxykarbonylpyrazol-1-yl)adenosinu a 2-(4-ethoxykarbonylpyrazol-1-yl)adenosinu |
CZ304053B6 (cs) | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu |
AU2013296420B2 (en) | 2012-08-01 | 2017-12-07 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
US9822141B2 (en) | 2012-08-01 | 2017-11-21 | Lewis And Clark Pharmaceuticals, Inc. | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
CZ305213B6 (cs) * | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy |
US9624258B2 (en) | 2013-05-30 | 2017-04-18 | Biophore India Pharmaceuticals Pvt. Ltd. | Polymorph of regadenoson |
CN104744540A (zh) * | 2013-12-26 | 2015-07-01 | 上海紫源制药有限公司 | 一种制备瑞加德松的方法 |
CN105085593A (zh) * | 2014-04-21 | 2015-11-25 | 上海紫源制药有限公司 | 瑞加德松的晶型及其制备方法 |
CN105198950B (zh) * | 2014-06-17 | 2018-10-02 | 上海紫源制药有限公司 | 一种瑞加德松晶型e的制备方法 |
CN105315284A (zh) * | 2014-07-23 | 2016-02-10 | 上海医药工业研究院 | 阿拉格列汀中间体的制备方法 |
US10442832B2 (en) | 2015-02-06 | 2019-10-15 | Apicore Us Llc | Process of making regadenoson and novel polymorph thereof |
US20180208622A1 (en) * | 2015-09-11 | 2018-07-26 | Sun Pharmaceutical Industries Limited | Stable crystalline form of regadenoson |
US10392417B2 (en) * | 2016-11-04 | 2019-08-27 | Apicore Us Llc | Polymorph of regadenoson and process for preparation thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1358191A (zh) * | 1999-06-22 | 2002-07-10 | Cv治疗公司 | N-吡唑a2a受体激动剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2495370A1 (en) * | 2002-08-15 | 2004-02-26 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
WO2006125190A1 (en) * | 2005-05-19 | 2006-11-23 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
PL1989214T3 (pl) * | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
-
2007
- 2007-05-17 CN CN2007800529263A patent/CN101668768B/zh active Active
- 2007-05-17 KR KR1020147007723A patent/KR20140041965A/ko not_active Application Discontinuation
- 2007-05-17 JP JP2010508354A patent/JP5349461B2/ja active Active
- 2007-05-17 MX MX2009012369A patent/MX2009012369A/es active IP Right Grant
- 2007-05-17 KR KR1020097026178A patent/KR101464794B1/ko active IP Right Grant
- 2007-05-17 PT PT77839009T patent/PT2158208E/pt unknown
- 2007-05-17 WO PCT/US2007/069190 patent/WO2008143667A1/en active Application Filing
- 2007-05-17 NZ NZ580940A patent/NZ580940A/en unknown
- 2007-05-17 CA CA2685589A patent/CA2685589C/en active Active
- 2007-05-17 ES ES07783900.9T patent/ES2537959T3/es active Active
- 2007-05-17 EP EP07783900.9A patent/EP2158208B1/en active Active
- 2007-05-17 AU AU2007353780A patent/AU2007353780B2/en active Active
-
2009
- 2009-10-28 ZA ZA2009/07565A patent/ZA200907565B/en unknown
- 2009-11-01 IL IL201856A patent/IL201856A/en active IP Right Grant
- 2009-12-16 NO NO20093543A patent/NO341758B1/no unknown
-
2010
- 2010-07-27 HK HK10107188.5A patent/HK1140771A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1358191A (zh) * | 1999-06-22 | 2002-07-10 | Cv治疗公司 | N-吡唑a2a受体激动剂 |
Non-Patent Citations (4)
Title |
---|
Kazunori Niiya,et al..2-(N’-Alkylidenehydrazino)adenosines: Potent and Selective Coronary Vasodilators.《J.Med.Chem.》.American Chemical Society,1992,第35卷(第24期),第4561页左栏第3段. * |
Medicinal Chemistry Letters》.Elsevier Science Ltd.,2002,第12卷(第20期),第2939页左栏参见附注17,第2936页左栏第2段. * |
Venkata P. Palle, et al..Structure–Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A2A Receptor.《Bioorganic & Medicinal Chemistry Letters》.Elsevier Science Ltd.,2002,第12卷(第20期),第2939页左栏参见附注17,第2936页左栏第2段. |
Venkata P. Palle, et al..Structure–Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A2A Receptor.《Bioorganic & * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397442A (zh) * | 2015-07-28 | 2017-02-15 | 国药集团国瑞药业有限公司 | 一种瑞加德松的纯化方法 |
CN106397442B (zh) * | 2015-07-28 | 2020-03-27 | 国药集团国瑞药业有限公司 | 一种瑞加德松的纯化方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2685589A1 (en) | 2008-11-27 |
AU2007353780A1 (en) | 2008-11-27 |
KR101464794B1 (ko) | 2014-11-27 |
IL201856A0 (en) | 2010-06-16 |
EP2158208A1 (en) | 2010-03-03 |
KR20140041965A (ko) | 2014-04-04 |
AU2007353780B2 (en) | 2013-11-14 |
JP2010527351A (ja) | 2010-08-12 |
PT2158208E (pt) | 2015-06-11 |
IL201856A (en) | 2013-07-31 |
NO341758B1 (no) | 2018-01-15 |
ZA200907565B (en) | 2011-10-26 |
KR20100021462A (ko) | 2010-02-24 |
WO2008143667A1 (en) | 2008-11-27 |
JP5349461B2 (ja) | 2013-11-20 |
NO20093543L (no) | 2009-12-16 |
CN101668768A (zh) | 2010-03-10 |
NZ580940A (en) | 2012-02-24 |
ES2537959T8 (es) | 2016-08-19 |
MX2009012369A (es) | 2009-12-01 |
EP2158208B1 (en) | 2015-04-08 |
CA2685589C (en) | 2014-09-16 |
HK1140771A1 (zh) | 2010-10-22 |
ES2537959T3 (es) | 2015-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101668768B (zh) | 制备a2a-腺苷受体激动剂及其多晶型物的方法 | |
USRE47301E1 (en) | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | |
CN101379073A (zh) | 制备一种a2a型腺苷受体激动剂及其多晶形物的方法 | |
CN102863494A (zh) | 制备a2a-腺苷受体激动剂及其多晶型物的方法 | |
RU2443708C2 (ru) | Способ получения агониста рецептора a2a-аденозина и его полиморфных модификаций | |
AU2014200786A1 (en) | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | |
MX2008009879A (en) | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: GILEAD PALO ALTO CO., LTD. Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD. Effective date: 20100519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20100519 Address after: American California Applicant after: Cv Therapeutics Inc. Address before: American California Applicant before: CV Therapeutics Inc. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GILEAD SCIENCES, INC. Free format text: FORMER OWNER: GILEAD PALO ALTO, INC. Effective date: 20120803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120803 Address after: American California Patentee after: Gilead Sciences Corporation Address before: American California Patentee before: Cv Therapeutics Inc. |
|
CB03 | Change of inventor or designer information |
Inventor after: Jeff.Zablocki Inventor after: Elzein Elfatih Inventor after: Robert Shimmel Inventor after: Travis Lemmens Inventor before: Jeff.Zablocki Inventor before: Elzein Elfatih |
|
COR | Change of bibliographic data |